View Future GrowthPharmagreen Biotech 過去の業績過去 基準チェック /06Pharmagreen Biotechは66.4%の年平均成長率で業績を伸ばしているが、Pharmaceuticals業界はgrowingで9.7%毎年増加している。売上は減少しており、年平均29.1%の割合である。主要情報66.44%収益成長率73.95%EPS成長率Pharmaceuticals 業界の成長5.95%収益成長率-29.10%株主資本利益率n/aネット・マージン-7,536.88%前回の決算情報31 Dec 2024最近の業績更新更新なしすべての更新を表示Recent updatesお知らせ • Dec 04Pharmagreen Biotech Inc. Files Form 15Pharmagreen Biotech Inc. has announced that it has filed a Form 15 with the Securities and Exchange Commission to voluntarily deregister its common under the Securities Exchange Act of 1934, as amended.お知らせ • May 13Pharmagreen Biotech Inc. announced delayed 10-Q filingOn 05/12/2023, Pharmagreen Biotech Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.お知らせ • Feb 09Pharmagreen Biotech, Inc. Launches Online Sales for Its MaxGenomic(TM) Supplement ProductPharmagreen Biotech Inc., announced that it has completed development of its first formulated nutraceutical product and has commenced online sales via the Shopify ecommerce platform of its MaxGenomic™ Supplement. The company is also pleased to have entered the nutraceutical industry with this product development and be part of this multi-hundred-billion-dollar industry that is growing at a record pace. MaxGenomic™ Supplement comes in a bottle with 60 Enteric capsules (delayed release), for a one- or two-month supply, depending on suggested use. This all-natural product utilizes a combination of fifteen ingredients from medicinal plants and medicinal mushrooms. Pharmagreen’s proprietary blend is unique to the market, by combining mushrooms and herbs in one, delayed release, capsule. A nutrigenomic supplement for the utmost mind and body experience. Nutrigenomics, or nutritional genomics, concerns the relationship between nutrients, diet, and genetic expression. The Company’s new product was formulated to help and assist with repairing damage done to your DNA. This damage happens during cell division and as a result of oxidative stresses due to environmental influences such as pollution. The human body has the ability to repair DNA with special proteins but over time these proteins get used up. By using fungi and plants that contain ß-glucans, polyinosinic-polycytidylic acid, lipopolysaccharides, and many more beneficial compounds it is possible to reverse damage done to your genes. Pharmagreen created this new line of genomic supplements because health and wellness start on the cellular level. Pharmagreen’s team focus is to help and aid, in the sales of MaxGenomic™ Supplement and additional nutraceutical products development. The company has plans to keep adding to the list of honorary sports ambassadors’ representatives. Pharmagreen’s near future plans also include launching additional products of its MaxGenomic™ brand designed for the extremely active, sports professionals and on the go individuals who are looking for immediate help and support before they begin and during their routine.お知らせ • Dec 29Pharmagreen Biotech Inc. announced delayed annual 10-K filingOn 12/28/2022, Pharmagreen Biotech Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC.お知らせ • Sep 09Pharmagreen Biotech Inc. Develops a Proprietary Nutraceutical Formulation and Prepares for Product LaunchPharmagreen Biotech Inc. announced that it has developed its first formulated nutraceutical product and is in the process of organizing the retail sales distribution channels for its new product. The Pharmagreen team is very excited to be launching this nutraceutical product utilizing a combination of fifteen ingredients from medicinal plants and mushrooms. Pharmagreen’s proprietary blend is unique to the market, a nutrigenomic supplement for the utmost mind and body experience. Nutrigenomics, or nutritional genomics, concerns the relationship between nutrients, diet, and genetic expression. The Company’s new product was formulated to repair damage done to your DNA. This damage happens during cell division and as a result of oxidative stresses due to environmental influences such as pollution. The human body has the ability to repair DNA with special proteins but over time these proteins get used up. By using fungi and plants that contain ß-glucans, polyinosinic-polycytidylic acid, lipopolysaccharides, and many more beneficial compounds it is possible to reverse damage done to your genes. Pharmagreen created this new line of genomic supplements because health and wellness start on the cellular level. This product, and new products as they become available, can be purchased through the Company's soon to be launched online store, Shopify, Amazon and other third-party online outlets. Utilizing the Company's expertise in plant genetics and proprietary tissue culture technologies, Pharmagreen's transgenic program uses the newest technology available to research and create nutraceuticals, protein-based formulations, and daily supplements with the potential to improve lives and address a wide variety of disease conditions.お知らせ • Aug 13Pharmagreen Biotech Inc. announced delayed 10-Q filingOn 08/12/2022, Pharmagreen Biotech Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.お知らせ • Feb 15Pharmagreen Biotech Inc. announced delayed 10-Q filingOn 02/14/2022, Pharmagreen Biotech Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.お知らせ • Aug 17Pharmagreen Biotech Inc. announced delayed 10-Q filingOn 08/16/2021, Pharmagreen Biotech Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.お知らせ • May 15Pharmagreen Biotech Inc. announced delayed 10-Q filingOn 05/14/2021, Pharmagreen Biotech Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.お知らせ • Feb 18Pharmagreen Biotech Inc. Signs LOI to Supply Crude CBD Oil Extracted from Certified Organically Grown Hemp BiomassPharmagreen Biotech Inc. announced that it has signed a Letter of Intent to supply hemp derived CBD oils extracted from organically grown hemp biomass with Advanced Bio-oil Technologies Ltd. PHBI and ABOT have commenced discussions under the Letter of Intent to begin the business development and to complete a definite on or before April 15, 2021 in the following areas: Pharmagreen will supply the raw CBD hemp oils for ABOT’s product development. Pharmagreen is moving ahead with its plans to set up an extraction facility in Nevada, U.S. and utilize its working relationship with its network of farmer(s) for the production of higher quality hemp oils from certified organically grown hemp biomass; ABOT has a qualified reg A offering from the SEC and to use this offering to raise up to $3 Million for the two projects. ABOT intends to use $1.5 Million for the construction of a certified formulation and product development where the product is being harvested or nearby and invest up to $1.5 Million for Pharmagreen to do the processing of organically grown hemp harvested in Nevada. There is no certainty at this preliminary stage the definite agreement will be concluded; PHBI and ABOT are interested to evolve its mutual relationship into further joint ventures. PHBI has extensive proven knowledge in the production of tissue culture starter plantlets, optimized cultivation techniques for growing large scale CBD hemp biomass as well as ability to produce any plant species plantlets using its proprietary tissue culture technologies. ABOT has developed a network of relationships globally for the manufacturing of products from botanical oils and sees the opportunity in working with PHBI to maximize the production of raw botanical biomass required. Pharmagreen Biotech Inc. announced that it has signed a Letter of Intent to supply hemp derived CBD oils extracted from organically grown hemp biomass with Advanced Bio-oil Technologies Ltd. PHBI and ABOT have commenced discussions under the Letter of Intent to begin the business development and to complete a definite on or before April 15, 2021 in the following areas: Pharmagreen will supply the raw CBD hemp oils for ABOT’s product development. Pharmagreen is moving ahead with its plans to set up an extraction facility in Nevada, U.S. and utilize its working relationship with its network of farmer(s) for the production of highest quality hemp oils from certified organically grown hemp biomass; ABOT has a qualified reg A offering from the SEC and to use this offering to raise up to $3 Million for the two projects. ABOT intends to use $1.5 Million for the construction of a certified formulation and product development where the product is being harvested or nearby and invest up to $1.5 Million for Pharmagreen to do the processing of organically grown hemp harvested in Nevada. There is no certainty at this preliminary stage the definite agreement will be concluded; PHBI and ABOT are interested to evolve its mutual relationship into further joint ventures. PHBI has extensive proven knowledge in the production of tissue culture starter plantlets, optimized cultivation techniques for growing large scale CBD hemp biomass as well as ability to produce any plant species plantlets using its proprietary tissue culture technologies. ABOT has developed a network of relationships globally for the manufacturing of products from botanical oils and sees the opportunity in working with PHBI to maximize the production of raw botanical biomass required.お知らせ • Feb 13Pharmagreen Biotech Inc. announced delayed 10-Q filingOn 02/12/2021, Pharmagreen Biotech Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.お知らせ • Dec 30Pharmagreen Biotech Inc. announced delayed annual 10-K filingOn 12/29/2020, Pharmagreen Biotech Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC.お知らせ • Aug 13Pharmagreen Biotech Inc. announced delayed 10-Q filingOn 08/12/2020, Pharmagreen Biotech Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.収支内訳Pharmagreen Biotech の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。収益と収入の歴史OTCPK:PHBI 収益、費用、利益 ( )USD Millions日付収益収益G+A経費研究開発費31 Dec 24000030 Sep 240-10030 Jun 24000031 Mar 240-10031 Dec 230-10030 Sep 230-10030 Jun 230-11031 Mar 23001031 Dec 220-11030 Sep 220-11030 Jun 220-21031 Mar 220-21031 Dec 210-41030 Sep 210-51030 Jun 210-51031 Mar 210-60031 Dec 200-30030 Sep 200-20030 Jun 200-20031 Mar 20001031 Dec 190-11030 Sep 190-11030 Jun 19001031 Mar 190-11031 Dec 180-11030 Sep 180-110質の高い収益: PHBIは現在利益が出ていません。利益率の向上: PHBIは現在利益が出ていません。フリー・キャッシュフローと収益の比較過去の収益成長分析収益動向: PHBIの過去 5 年間の前年比収益成長率がプラスであったかどうかを判断するにはデータが不十分です。成長の加速: PHBIの過去 1 年間の収益成長を 5 年間の平均と比較することはできません。現在は利益が出ていないためです。収益対業界: PHBIは利益が出ていないため、過去 1 年間の収益成長をPharmaceuticals業界 ( -5% ) と比較することは困難です。株主資本利益率高いROE: PHBIの負債は資産を上回っているため、自己資本利益率を計算することは困難です。総資産利益率使用総資本利益率過去の好業績企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 、過去の業績が好調な企業。View Financial Health企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/24 04:29終値2026/05/22 00:00収益2024/12/31年間収益2024/09/30データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Pharmagreen Biotech Inc. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
お知らせ • Dec 04Pharmagreen Biotech Inc. Files Form 15Pharmagreen Biotech Inc. has announced that it has filed a Form 15 with the Securities and Exchange Commission to voluntarily deregister its common under the Securities Exchange Act of 1934, as amended.
お知らせ • May 13Pharmagreen Biotech Inc. announced delayed 10-Q filingOn 05/12/2023, Pharmagreen Biotech Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
お知らせ • Feb 09Pharmagreen Biotech, Inc. Launches Online Sales for Its MaxGenomic(TM) Supplement ProductPharmagreen Biotech Inc., announced that it has completed development of its first formulated nutraceutical product and has commenced online sales via the Shopify ecommerce platform of its MaxGenomic™ Supplement. The company is also pleased to have entered the nutraceutical industry with this product development and be part of this multi-hundred-billion-dollar industry that is growing at a record pace. MaxGenomic™ Supplement comes in a bottle with 60 Enteric capsules (delayed release), for a one- or two-month supply, depending on suggested use. This all-natural product utilizes a combination of fifteen ingredients from medicinal plants and medicinal mushrooms. Pharmagreen’s proprietary blend is unique to the market, by combining mushrooms and herbs in one, delayed release, capsule. A nutrigenomic supplement for the utmost mind and body experience. Nutrigenomics, or nutritional genomics, concerns the relationship between nutrients, diet, and genetic expression. The Company’s new product was formulated to help and assist with repairing damage done to your DNA. This damage happens during cell division and as a result of oxidative stresses due to environmental influences such as pollution. The human body has the ability to repair DNA with special proteins but over time these proteins get used up. By using fungi and plants that contain ß-glucans, polyinosinic-polycytidylic acid, lipopolysaccharides, and many more beneficial compounds it is possible to reverse damage done to your genes. Pharmagreen created this new line of genomic supplements because health and wellness start on the cellular level. Pharmagreen’s team focus is to help and aid, in the sales of MaxGenomic™ Supplement and additional nutraceutical products development. The company has plans to keep adding to the list of honorary sports ambassadors’ representatives. Pharmagreen’s near future plans also include launching additional products of its MaxGenomic™ brand designed for the extremely active, sports professionals and on the go individuals who are looking for immediate help and support before they begin and during their routine.
お知らせ • Dec 29Pharmagreen Biotech Inc. announced delayed annual 10-K filingOn 12/28/2022, Pharmagreen Biotech Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC.
お知らせ • Sep 09Pharmagreen Biotech Inc. Develops a Proprietary Nutraceutical Formulation and Prepares for Product LaunchPharmagreen Biotech Inc. announced that it has developed its first formulated nutraceutical product and is in the process of organizing the retail sales distribution channels for its new product. The Pharmagreen team is very excited to be launching this nutraceutical product utilizing a combination of fifteen ingredients from medicinal plants and mushrooms. Pharmagreen’s proprietary blend is unique to the market, a nutrigenomic supplement for the utmost mind and body experience. Nutrigenomics, or nutritional genomics, concerns the relationship between nutrients, diet, and genetic expression. The Company’s new product was formulated to repair damage done to your DNA. This damage happens during cell division and as a result of oxidative stresses due to environmental influences such as pollution. The human body has the ability to repair DNA with special proteins but over time these proteins get used up. By using fungi and plants that contain ß-glucans, polyinosinic-polycytidylic acid, lipopolysaccharides, and many more beneficial compounds it is possible to reverse damage done to your genes. Pharmagreen created this new line of genomic supplements because health and wellness start on the cellular level. This product, and new products as they become available, can be purchased through the Company's soon to be launched online store, Shopify, Amazon and other third-party online outlets. Utilizing the Company's expertise in plant genetics and proprietary tissue culture technologies, Pharmagreen's transgenic program uses the newest technology available to research and create nutraceuticals, protein-based formulations, and daily supplements with the potential to improve lives and address a wide variety of disease conditions.
お知らせ • Aug 13Pharmagreen Biotech Inc. announced delayed 10-Q filingOn 08/12/2022, Pharmagreen Biotech Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
お知らせ • Feb 15Pharmagreen Biotech Inc. announced delayed 10-Q filingOn 02/14/2022, Pharmagreen Biotech Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
お知らせ • Aug 17Pharmagreen Biotech Inc. announced delayed 10-Q filingOn 08/16/2021, Pharmagreen Biotech Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
お知らせ • May 15Pharmagreen Biotech Inc. announced delayed 10-Q filingOn 05/14/2021, Pharmagreen Biotech Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
お知らせ • Feb 18Pharmagreen Biotech Inc. Signs LOI to Supply Crude CBD Oil Extracted from Certified Organically Grown Hemp BiomassPharmagreen Biotech Inc. announced that it has signed a Letter of Intent to supply hemp derived CBD oils extracted from organically grown hemp biomass with Advanced Bio-oil Technologies Ltd. PHBI and ABOT have commenced discussions under the Letter of Intent to begin the business development and to complete a definite on or before April 15, 2021 in the following areas: Pharmagreen will supply the raw CBD hemp oils for ABOT’s product development. Pharmagreen is moving ahead with its plans to set up an extraction facility in Nevada, U.S. and utilize its working relationship with its network of farmer(s) for the production of higher quality hemp oils from certified organically grown hemp biomass; ABOT has a qualified reg A offering from the SEC and to use this offering to raise up to $3 Million for the two projects. ABOT intends to use $1.5 Million for the construction of a certified formulation and product development where the product is being harvested or nearby and invest up to $1.5 Million for Pharmagreen to do the processing of organically grown hemp harvested in Nevada. There is no certainty at this preliminary stage the definite agreement will be concluded; PHBI and ABOT are interested to evolve its mutual relationship into further joint ventures. PHBI has extensive proven knowledge in the production of tissue culture starter plantlets, optimized cultivation techniques for growing large scale CBD hemp biomass as well as ability to produce any plant species plantlets using its proprietary tissue culture technologies. ABOT has developed a network of relationships globally for the manufacturing of products from botanical oils and sees the opportunity in working with PHBI to maximize the production of raw botanical biomass required. Pharmagreen Biotech Inc. announced that it has signed a Letter of Intent to supply hemp derived CBD oils extracted from organically grown hemp biomass with Advanced Bio-oil Technologies Ltd. PHBI and ABOT have commenced discussions under the Letter of Intent to begin the business development and to complete a definite on or before April 15, 2021 in the following areas: Pharmagreen will supply the raw CBD hemp oils for ABOT’s product development. Pharmagreen is moving ahead with its plans to set up an extraction facility in Nevada, U.S. and utilize its working relationship with its network of farmer(s) for the production of highest quality hemp oils from certified organically grown hemp biomass; ABOT has a qualified reg A offering from the SEC and to use this offering to raise up to $3 Million for the two projects. ABOT intends to use $1.5 Million for the construction of a certified formulation and product development where the product is being harvested or nearby and invest up to $1.5 Million for Pharmagreen to do the processing of organically grown hemp harvested in Nevada. There is no certainty at this preliminary stage the definite agreement will be concluded; PHBI and ABOT are interested to evolve its mutual relationship into further joint ventures. PHBI has extensive proven knowledge in the production of tissue culture starter plantlets, optimized cultivation techniques for growing large scale CBD hemp biomass as well as ability to produce any plant species plantlets using its proprietary tissue culture technologies. ABOT has developed a network of relationships globally for the manufacturing of products from botanical oils and sees the opportunity in working with PHBI to maximize the production of raw botanical biomass required.
お知らせ • Feb 13Pharmagreen Biotech Inc. announced delayed 10-Q filingOn 02/12/2021, Pharmagreen Biotech Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
お知らせ • Dec 30Pharmagreen Biotech Inc. announced delayed annual 10-K filingOn 12/29/2020, Pharmagreen Biotech Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC.
お知らせ • Aug 13Pharmagreen Biotech Inc. announced delayed 10-Q filingOn 08/12/2020, Pharmagreen Biotech Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.